AMPIO PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ampiopharma.com
A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Biological: 4 mL injection of AmpionDrug: 4 mL Injection of Placebo
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 342
- Registration Number
- NCT02242435
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Inc., Englewood, Colorado, United States
A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain
Phase 1
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Biological: 4 mL injection of AmpionDrug: 4 mL injection of Placebo
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02184156
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Englewood, Colorado, United States
A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee
Phase 3
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: 4 mL Injection of PlaceboBiological: 4 mL injection of Ampion
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 538
- Registration Number
- NCT02024529
An Efficacy and Safety Study of Two Doses of Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
Phase 2
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Biological: 4 mL injection of AmpionDrug: 10 mL Injection of PlaceboDrug: 4 mL Injection of PlaceboBiological: 10 mL Injection of Ampion
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 329
- Registration Number
- NCT01839331
A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 354
- Registration Number
- NCT01821677
© Copyright 2025. All Rights Reserved by MedPath